Dr Reddy's Laboratories, the country's second biggest drug maker, revealed an unexpected consolidated net loss of Rs 522 crore in the October-December quarter, due to a writedown of intangible assets and goodwill in its German arm, Betapharm.
Nine Indian Americans are running for the US House of Representatives, which includes a re-election bid by six of them while three are making their maiden foray into Congressional politics.
Dr. K. Anji Reddy, Founder and Chairman of Dr. Reddy's Laboratories, died at a hospital in Hyderabad on Friday. He was 72.
Dr Reddy's Laboratories plans to brand its speciality drugs sold in the US. It will begin selling branded skin care products by year-end. The venture will be spearheaded by Promius Pharma, a wholly owned subsidiary of its US arm
Global drug maker Dr Reddy's Laboratories is adding 1,300 people this year, including about 350 through campus recruitment, according to Prabir Kumar Jha, DRL's senior vice-president and global chief.
Dr Reddys Laboratories surged in early trades on Friday on good buying support, but it slipped from the days high. The scrip of the local pharmaceutical major continued to witness volatility.
The $66 million (Rs 272.8 crore) Leiner Health Products is likely to sue DRL for the early divorce (the agreement has lasted only four years) from the alliance.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
Pharmaceutical major Dr Reddy's Laboratories Ltd on Tuesday said it will offer up to 13.5 million American Depositary Shares.
Dr Reddy's Laboratories on Saturday reported a 93.79 per cent increase in consolidated net profit at Rs 90.91 crore (Rs 909.1 million) for the second quarter ended September 30, 2005
In November, DRL registered growth of 28 per cent year-on-year (YoY), which was the highest among peers and double that of the industry growth (14.5 per cent).
Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?
After sealing the area of the nitrogen gas leak that left two persons dead, Dr Reddy's Laboratories (DRL) is to be served a notice on the incident that occured at its manufacturing plant at Bollaram on the outskirts of Hyderabad.
The Sensex finished 38 points higher at 3,640 on Thursday. The Nifty closed with a gain of 12 points at 1,146.
Indian drug maker Dr Reddy's Laboratories said on Friday its fiscal 2003 profit fell 28 per cent, on lower sales of a Prozac generic drug to the key US market and slowing domestic sales.\n\n\n\n
The list, posted on a website link launched by the US regulator, includes ABB, HSBC, Nokia, Unilever, Cadbury, Total and Siemens among others.
Dr Reddy's Laboratories Limited aims to increase the R&D spend on its three major research programmes, including the reverse cholesterol transport area, in a bid to come out with pathbreaking molecules in the next 7-10 years.
A three-member committee, comprising two officials from the Director of Factories and one pharma expert, will probe the gas leak at a production unit of Dr Reddy's Laboratories (DRL). The Director of Factories will appoint a pharma domain expert soon.
DRL launched four new products in North America during the previous quarter.
The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
Gland Pharma beat muted expectations for Q2FY25. There was increased Ebitda (Earnings before interest, taxes, depreciation and amortisation) loss at Cenexi, the CRAM subsidiary. However, overall Ebitda margin was better than expectations at 21.1 per cent. But given two years of earnings decline in FY23 and FY24, the business may have bottomed and upper-teens EPS (earnings per share) growth looks possible over next two financial years.
Dr Reddy's Laboratories, the second largest drug maker in the country, would invest about Rs 750 crore.
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had filed an application with the US Food and Drug Administration to market a generic form of GlaxoSmithKline's anti-nausea drug Zofran.\n\n
Dr Reddy's has offered a price of 0.52 euro in cash for each OctoPlus share.
The company has launched only 3 new products during 2015 when compared to 14 launches in 2014
Apart from favipiravir and remdesivir, its key Covid-19 products, DRL has already launched nutraceutical products and hand sanitisers during the pandemic.
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.
Dr Reddys Laboratories Ltd has posted a net profit of Rs 931.60 million for the quarter ended December 31, 2002 as compared to a net profit of Rs 1615.30 million in the quarter ended December 31,2001.
In recent months, several pharma multinational corporations (MNCs) are increasingly turning to Indian companies to expand market reach in the country's pharmaceuticals sector. Sanofi's partnerships with Dr Reddy's, Cipla, and Emcure, AstraZeneca and Mankind Pharma - teaming up for asthma medication distribution - are a few instances of this trend. This strategy allows MNCs to leverage established Indian networks and reach a wider audience. Indian companies also benefit from global brands and expertise, say analysts.
There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
These are the top buyers of the scrapped electoral bonds, the data for which was released by the Election Commission on Thursday.
A reading of the reports suggests that there is no standard practice for reporting political contributions and it is left to the company's discretion to report them as they find fit.
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances